ArticleNature and science of sleep2025
Mediation Effect of Relaxin in Cerebrospinal Fluid on the Association Between Smoking and Sleep.
Article in Nature and science of sleep, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study investigates the influence of CSF relaxin (RLN) on the association between smoking and sleep quality, considering previous findings linking smoking and RLN with psychiatric conditions. Methods: In a case-control study of 168 Chinese adult males (70 smokers, 98 non-smokers), levels of relaxin in cerebrospinal fluid (CSF) were measured. Sleep quality was assessed using the Pittsburgh Sleep Quality Index (PSQI), comprising seven scales. Logistic regression and mediation models analyzed the relationships between nicotine dependence, PSQI scores, and CSF relaxin. Logistic regression examined the interaction of nicotine dependence and relaxin gene on PSQI subdimension scores. Results: Smokers exhibited more severe sleep problems in PSQI total score and four PSQI subdimension scores (p < 0.05). CSF relaxin levels were significantly higher in smokers (20.7 ± 7.0 vs 16.3 ± 6.5, p < 0.001) and correlated closely with PSQI total score (r = 0.275, p < 0.001). Logistic regression found that CSF relaxin associated with PSQI subdimension scores, particularly in sleep disturbance (OR = 3.07 (1.61-5.99), adjusted p < 0.01). Mediation analysis indicated relationship between nicotine dependence and PSQI total score, with CSF relaxin as a mediator, and the indirect effect accounted for 25% of the total effect (Indirect effect = 0.124 (0.021-0.223), Total effect = 0.494 (0.193-0.807)). Additionally, polymorphisms in gene of relaxin and its receptors were closely tied to smoking behaviors and sleep quality (p < 0.05). Conclusion: CSF relaxin levels were significantly elevated in smokers and closely associated with PSQI subdimension scores, particularly with the sleep disturbance subdimension score. Moreover, CSF relaxin mediated the relationship between nicotine dependence and sleep quality. Polymorphisms (RLN3 rs12327666, rs1982632, and rs7249702, RLN3R1 rs35399, and RLN3R2 rs11264422) also played a role in smoking behaviors or sleep quality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.